Table 3.
Simultaneous MMF/tacrolimus/corticosteroid therapy
| Case No. | Gender | Race | Age at onset, years | Age at start of combination therapy, years | Renal pathology | Previous immunosuppressants | Duration of combination therapy, months | Response to combination therapy | Response time, months | Lowest known UP/Cr | Final eGFR, ml/min/1.73 m2 | Final serum albumin, mg/dl | Follow-up, months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRNS | |||||||||||||
| 1 | male | South Asian | 2 | 4 | MCNS | pred, tac, rituximab | 11 | PR | 6 | 1.23 | 140.3 | 3.7 | 11 |
| 2 | female | South Asian | 1.5 | 6 | MCNS | pred, levamisole, cyclo, MMF | 15 | CR | <1 | 0.08 | 153.7 | 4 | 15 |
| 3 | male | South Asian | 3.2 | 5 | MCNS | pred, tac, rituximab | 11 | CR | 6 | 0.14 | 206.9 | 3.8 | 11 |
|
SDNS | |||||||||||||
| 4 | male | African-American | 10.4 | 19 | MCNS | pred, cyclo, MMF, tac | 4 | NR | 0.07 | 124.2 | 3.3 | 10 | |
| 5 | male | Caucasian | 8.6 | 9 | MCNS | pred, MMF | 6 | CR | <1 | 0.08 | 135.7 | 4.5 | 10 |
| 6 | male | Asian | 8 | 11 | FSGS | pred, MMF | 8 | NR | 7.22 | 48.5 | 1.5 | 75 | |
|
SSNS | |||||||||||||
| 7 | male | Asian | 2 | 17 | MCNS | pred, cyclo, MMF | 39 | CR | 6 | 0.05 | 156.3 | 4.2 | 45 |
| 8 | female | Caucasian | 2.8 | 7 | FSGS | pred, cyclo, tac | 6 | CR | 1 | 0.19 | 103.3 | 4 | 6 |
pred = Prednisone; tac = tacrolimus; cyclo = cyclosporine; PR = partial remission; CR = complete remission; NR = no remission.